Cagrilintide Canada: Research Peptide Overview
What Cagrilintide is, which receptors it acts on, how it differs from the incretin peptides it is listed beside, and what the published batch data shows.
Cagrilintide is a synthetic research peptide studied in laboratory and preclinical settings for its activity at the amylin receptor, and — less often mentioned, but just as relevant to what is actually being measured — at the calcitonin receptor. It appears most frequently in work on metabolic signalling, appetite-related pathways, and hormone-mediated regulatory mechanisms.
This guide covers what the compound is, what the verified chemistry says, how NexPept documents each batch, and what to check when sourcing it in Canada. It is an educational overview for laboratory research purposes and is not a dosing guide.
Cagrilintide (CAS 1415456-99-3, development code AM833) is a long-acting 37-residue amylin analogue acting at both the amylin and calcitonin receptors. NexPept stocks it as a 10mg lyophilized vial, current lot NP-CAGRI-02 at 99.42% HPLC purity, tested August 17, 2026 — with the certificate published up front, not supplied on request. Research use only.
What Is Cagrilintide?
Cagrilintide, also seen under the development codes AM833 and NN0174-0833, is a long-acting analogue of human amylin — the 37-residue peptide hormone co-secreted with insulin. The research-grade material is a 37-amino-acid peptide carrying three structural modifications that separate it from native amylin: a lipid side chain (an eicosanedioic acid moiety attached through a γ-glutamate linker at the N-terminal lysine), an intramolecular disulfide bridge between the cysteine residues at positions 3 and 8, and an amidated C-terminus.
Those modifications are the reason it behaves as a long-acting analogue in experimental systems rather than as a short-lived native peptide. They are also why lot-to-lot consistency matters more here than for a short unmodified sequence: a failed lipidation step or an incomplete disulfide closure produces material that looks correct on a label and does not behave the same in an assay.
If you are new to this category of material, our guide explaining what research peptides are is a useful starting point.
Cagrilintide Properties
The figures below are the published identifiers for the compound. The purity and batch values specific to the material NexPept ships are in the batch section further down.
| Property | Value |
|---|---|
| CAS Number | 1415456-99-3 |
| Development codes | AM833, AM-833, NN0174-0833 |
| Compound class | Long-acting synthetic amylin analogue |
| Receptor targets | Amylin receptor (AMYR) and calcitonin receptor (CTR) |
| Sequence length | 37 amino acids |
| Molecular formula | C194H312N54O59S2 |
| Molecular weight | 4409.00 g/mol |
| Structural features | N-terminal lipidation via γ-Glu linker; Cys3–Cys8 disulfide bridge; C-terminal amide |
| Physical form | Lyophilized powder, white to off-white |
| Available format | 10mg vial |
| Analytical method | HPLC purity, mass spectrometry identity confirmation |
| Regulatory status | Not authorized by Health Canada for human or veterinary use |
Mechanism of Interest: Amylin and Calcitonin Receptors
Cagrilintide is characterized in the literature as a non-selective agonist at both the amylin receptor and the calcitonin receptor. That dual activity is the part worth understanding, because secondary sources routinely describe it as an amylin compound alone, which understates what is being measured in an assay.
The amylin receptor is not a single protein. It is a complex: the calcitonin receptor paired with one of three receptor activity-modifying proteins. A compound that engages the calcitonin receptor directly and the amylin receptor complex therefore produces a signalling profile that is harder to attribute cleanly to one pathway — which is precisely why it turns up in selectivity and cross-reactivity studies rather than in simple single-target binding work.
In experimental settings this makes it useful for evaluating how peptide-based signalling influences coordinated responses across systems, and for comparative work alongside compounds acting on the incretin receptors instead.
Research Focus Areas
In controlled laboratory environments, Cagrilintide appears in work on:
- Amylin receptor binding and interaction
- Calcitonin receptor cross-reactivity and selectivity profiling
- Peptide–receptor signalling dynamics
- Appetite-related signalling pathways
- Metabolic regulation models
- Hormonal coordination across experimental systems
- Comparative work against incretin-pathway peptides
All of this is preclinical and confined to experimental contexts. Interpretation should be limited strictly to laboratory data.
How Cagrilintide Differs From Incretin-Pathway Peptides
Cagrilintide is routinely listed beside the incretin peptides, but it acts on a different receptor family from them entirely. That distinction is the reason it appears in combination-study designs rather than as a substitute: the pathways are separate, so the research question is usually how two signalling systems interact, not which single compound is more potent.
| Compound | Receptor targets | Class |
|---|---|---|
| Cagrilintide | Amylin receptor (AMYR), calcitonin receptor (CTR) | Long-acting amylin analogue |
| Tirzepatide | GLP-1 receptor, GIP receptor | Dual incretin agonist |
| Retatrutide | GLP-1 receptor, GIP receptor, glucagon receptor | Triple agonist |
Cagrilintide and the other receptor-targeting compounds in our catalogue are grouped under receptor research.
Purity, Batch Data and Documentation
Purity is what determines whether a result is reproducible. With a lipidated, disulfide-bridged peptide the realistic failure modes are not gross contamination — they are incomplete modification and closely related process impurities that a chromatogram will show and a typed purity figure will not.
"COA available on request" is the most over-claimed phrase in this market. A certificate worth relying on names the testing laboratory, carries a lot number matching the vial in your hand, states the analytical method, and shows the chromatogram rather than a number someone typed. We publish ours instead of supplying them on request, so the material can be checked before an order is placed.
| Format | Batch | Tested | HPLC purity | Report |
|---|---|---|---|---|
| Cagrilintide 10mg | NP-CAGRI-02 | Aug 17, 2026 | 99.42% | View COA |
Identity and purity are confirmed by HPLC and mass spectrometry before a lot is listed, and the certificate stays published in our COA library after the batch sells out — so a result recorded against an old lot can still be traced back to its report. All new batches additionally carry endotoxin testing, which matters for cell-based work where endotoxin can confound a result independently of chemical purity, and the most-ordered products also carry heavy-metal testing.
Storage and Handling
Lyophilized peptide material is comparatively stable, but what happens after delivery affects integrity more than most buyers expect. General laboratory considerations include:
- Storage cool and dry, avoiding repeated temperature cycling
- Protection from moisture and prolonged light exposure
- Recording the lot number against your own inventory, so any later question about a result traces back to a specific batch and its report
- Handling under institution-approved protocols
Lyophilized powder is generally far more stable than peptide in solution, and researchers should defer to their own institution's validated protocols rather than a general guideline. More detail is in our guide to storing research peptides. NexPept does not supply preparation, reconstitution or handling instructions; those are determined by qualified personnel under your own protocols.
Sourcing Cagrilintide in Canada
Four things are worth checking before ordering anywhere. They apply to any supplier rather than to this compound specifically.
Documentation
Batch-specific reports, published rather than promised, with a lot number that matches your vial. One generic certificate covering a whole catalogue tells you nothing about what actually arrived. Ask whether a COA can be confirmed directly with the issuing laboratory — if the answer is anything other than yes, that is the answer.
Fulfilment
A stated Canadian location and courier. Material crossing the border is subject to customs holds nobody can give you a date for, and spends longer in uncontrolled conditions. Our orders ship from Ontario by tracked Canada Post — details on the shipping page.
Positioning
Research-use framing throughout. A supplier offering dosing guidance or personal-use language is operating outside that framing, which tells you something about how the rest of the operation is run.
Pricing
Analytical testing costs money per lot. A catalogue priced well below everyone else has usually removed a cost somewhere, and testing is the easiest one to remove while still describing material as tested. For a wider walkthrough of evaluating a domestic supplier, see our guide to buying research peptides in Canada.
Common Questions About Cagrilintide
What is Cagrilintide?
A long-acting synthetic analogue of human amylin, 37 amino acids long, modified with an N-terminal lipid chain, a Cys3–Cys8 disulfide bridge and an amidated C-terminus. It is also referred to by its development code AM833. NexPept supplies it as a lyophilized research reference standard only.
What receptors does Cagrilintide act on?
It is described in the literature as a non-selective agonist at the amylin receptor and the calcitonin receptor. Because the amylin receptor complex is itself built on the calcitonin receptor, that dual activity is a frequent subject of selectivity and cross-reactivity work.
Is Cagrilintide approved in Canada?
No. Cagrilintide is not authorized by Health Canada for human or veterinary use and is not an approved drug. It is supplied strictly as a laboratory research material.
What testing does each batch go through?
Identity and purity are confirmed by HPLC and mass spectrometry before a lot is listed, and the certificate is published with its batch number, purity figure and test date. The current lot, NP-CAGRI-02, tested at 99.42% on August 17, 2026. New batches also carry endotoxin testing. If a lot has not been tested, it is not sold.
How does Cagrilintide compare with Tirzepatide or Retatrutide?
They act on different receptor families. Tirzepatide and Retatrutide target the incretin receptors; Cagrilintide targets the amylin and calcitonin receptors. In research designs they are therefore studied alongside one another rather than as alternatives.
How should it be stored?
Storage follows your own laboratory protocols. In general terms: cool, dry, sealed, protected from light and moisture, with lot numbers recorded against your inventory.
Key Takeaways
- Cagrilintide (AM833) is a long-acting 37-residue amylin analogue, CAS 1415456-99-3
- It acts at both the amylin and the calcitonin receptor, not amylin alone
- It sits in a different receptor family from Tirzepatide and Retatrutide, so it is studied alongside them rather than as a substitute
- The current NexPept lot, NP-CAGRI-02, tested at 99.42% by HPLC on August 17, 2026, with the certificate published up front
- It is not authorized by Health Canada and is supplied for laboratory research use only
Source Cagrilintide in Canada
Batch-tracked, third-party tested, certificate published before you order, and shipped from Ontario by tracked Canada Post.
View Cagrilintide 10MGPeer-reviewed literature on this compound is indexed on PubMed, and the full NexPept catalogue of lab-tested compounds is available here.